Standout Papers
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2013)
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) (2014)
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (2016)
Immediate Impact
2 by Nobel laureates 15 from Science/Nature 125 standout
Citing Papers
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 Standout
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
Works of Chun‐Ming Tsai being referenced
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
2018
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
2014 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Chun‐Ming Tsai | 6266 | 5227 | 1400 | 2013 | 112 | 7.6k | |
| Caicun Zhou | 6649 | 6319 | 1614 | 2518 | 135 | 8.7k | |
| Ki Hyeong Lee | 6914 | 6550 | 1490 | 2089 | 195 | 9.2k | |
| David M. Jackman | 5496 | 4838 | 1636 | 2003 | 87 | 7.4k | |
| Helen Mann | 4433 | 4000 | 1192 | 1592 | 89 | 5.9k | |
| Chee Khoon Lee | 4817 | 5043 | 1566 | 1739 | 169 | 7.2k | |
| Naoyuki Nogami | 5260 | 5727 | 944 | 1353 | 146 | 7.2k | |
| Eng Huat Tan | 4646 | 4536 | 1027 | 1649 | 55 | 6.7k | |
| Akira Inoue | 5416 | 4926 | 920 | 1727 | 189 | 7.0k | |
| Rogério Lilenbaum | 5344 | 5515 | 1208 | 2115 | 105 | 8.3k | |
| Alessandro Morabito | 3306 | 4633 | 1653 | 1629 | 213 | 7.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...